- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 28, 2025
Distillery Therapeutics
RUNX1 inhibition via dominant negative mRNA construct for vitreoretinal disease
BioCentury | Jul 25, 2019
Translation in Brief
Neoantigens in pediatric ALL could lead to cell-based therapies
Why a St. Jude's team thinks pediatric leukemia could be treated with neoantigen-targeted cell therapies
BioCentury | Apr 30, 2019
Distillery Therapeutics
RUNX1, RUNX3, CBFB and PMP22 as targets for neurofibromatosis
BioCentury | Mar 12, 2015
Distillery Therapeutics
Therapeutics: Core-binding factor β subunit (CBFB; CBF-β); myosin heavy chain 11 smooth muscle (MYH11; SMMHC); runt-related transcription factor 1 (RUNX1)
Items per page:
1 - 10 of 13